|
|
Volumn 92, Issue 9, 2000, Pages 683-684
|
|
Herceptin in the adjuvant setting: phase III trials begin.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
MONOCLONAL ANTIBODY;
PACLITAXEL;
TRASTUZUMAB;
ARTICLE;
BREAST TUMOR;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
FEMALE;
HUMAN;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CLINICAL TRIALS, PHASE III;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
FEMALE;
HUMANS;
PACLITAXEL;
RANDOMIZED CONTROLLED TRIALS;
|
|
EID: 0034600160
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/92.9.683 Document Type: Article |
|
Times cited : (11)
|
|
References (0)
|
